MediciNova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, targeting the U.S. market. Its primary product candidates are MN-166 (ibudilast) for neurological disorders including progressive multiple sclerosis, ALS, chemotherapy-induced peripheral neuropathy, and glioblastoma, and MN-001 (tipelukast) for fibrotic and metabolic disorders including NAFLD and hypertriglyceridemia. The company has no approved products and relies on clinical-stage development.
Q2 FY2026 — expected 2026-07-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001193125-26-100432 | EDGAR | 57K words |
| 2025-02-19 | 2024-12-31 | 0000950170-25-023301 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0000950170-24-015920 | EDGAR | — |
| 2023-02-16 | 2022-12-31 | 0000950170-23-003054 | EDGAR | — |
| 2022-02-16 | 2021-12-31 | 0001564590-22-005388 | EDGAR | — |
| 2021-02-19 | 2020-12-31 | 0001564590-21-006771 | EDGAR | — |
| 2020-02-13 | 2019-12-31 | 0001564590-20-004605 | EDGAR | — |
| 2019-02-13 | 2018-12-31 | 0001564590-19-002835 | EDGAR | — |
| 2018-02-13 | 2017-12-31 | 0001564590-18-001957 | EDGAR | — |
| 2017-02-14 | 2016-12-31 | 0001564590-17-001547 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277779 | EDGAR | 15K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-109041 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070461 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126343 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094092 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056996 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062079 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040621 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021279 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001564590-22-037391 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001564590-22-029126 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019872 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-20 | 0001193125-26-060232 | EDGAR | 13K words |
| 2025-12-30 | 0001193125-25-335917 | EDGAR | — |
| 2025-08-01 | 0001193125-25-170744 | EDGAR | — |
| 2025-06-18 | 0000950170-25-087924 | EDGAR | — |
| 2025-03-11 | 0001193125-25-051990 | EDGAR | — |
| 2024-06-12 | 0000950170-24-072461 | EDGAR | — |
| 2024-04-01 | 0001193125-24-083356 | EDGAR | — |
| 2023-08-07 | 0001193125-23-204956 | EDGAR | — |
| 2023-06-22 | 0001193125-23-172585 | EDGAR | — |
| 2023-06-14 | 0000950170-23-027823 | EDGAR | — |
423 total filings indexed. 391 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001226616 |
| Ticker | MNOV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.medicinova.com |
| Listed | 2006-12-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report